HIV Infections Clinical Trial
— TEXTR34Official title:
RCT of a Text Messaging Adherence Assessment & Intervention Tool for Rural HIV+ Drug Users
| Verified date | February 2018 |
| Source | University of Virginia |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The investigators will develop and test the feasibility and promise of a combined HIV
adherence assessment and intervention application for rural drug users using an available,
familiar technology whose reach will grow exponentially: text messaging via mobile phones. By
2007, 84% of U.S. residents had mobile phones, with near 100% mobile phone penetration
projected by 2013. While technology adoption is often slower in under-served communities, the
trend is different with mobile phone technology. African-Americans are using more mobile
phone minutes per capita and increasing their use at a higher rate compared with other ethnic
groups. This technology has great potential to reduce health disparities. In this project,
the investigators will develop and test the feasibility and promise of a text messaging
application and system using Ecological Momentary Assessment methods to detect nonadherence
and drug use and immediately intervene to improve HIV treatment adherence in drug users
living with HIV/AIDS who reside outside major metropolitan areas. This R34 is a Stage 1b/2a
project in the Stage Model of Behavioral Therapy Development that will develop novel
interventions and methods, and generate preliminary estimates of effect sizes that will
determine whether a larger clinical trial with extended follow-up and cost-effectiveness
evaluation is warranted.
The specific aims of this project are:
1. To identify assessment and intervention features relevant to the adherence barriers and
drug use patterns of rural and non-urban HIV+ drug users using formative methods
including:
- structured interviews and focus groups to identify specific barriers to adherence
and engagement in care and needs related to drug craving and drug use that should
be addressed by the intervention
- iterative usability testing of components and drafts of the intervention
2. To create a text messaging mobile phone application and system (Treatment Extension by
Texting, Text) to assess and improve HIV treatment adherence and drug use in real time
--Text will be built upon a piloted unidirectional personalized text phone application
and system, STeM, and will include pre- and post-programming usability testing
3. To test the feasibility and promise of the assessment and intervention tool in a
randomized pilot trial of rural HIV+ drug users with detectable viral load (VL)
comparing Text to usual care
- Feasibility: Identify recruitment rates, consent rates, participant flow,
completion rates, and variance of key covariates and outcome variables
- Promise: determine point estimates and the precision of effects for primary and
secondary adherence outcomes including pharmacy refills and unannounced pill counts
(medication adherence), missed visit percentage (treatment engagement), VL, and
drug craving and drug use.
| Status | Completed |
| Enrollment | 54 |
| Est. completion date | December 2013 |
| Est. primary completion date | September 2013 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - 18 or older - has a detectable viral load - reports use of at least one illicit drug in last 30 days - requires ART - able to receive mobile phone service at home address Exclusion Criteria: - lack of English proficiency - planning to move out of area in the next six months - inability to provide consent. Note regarding "inability to provide consent": Traditionally, some patients with HIV whom we evaluate for potential participation in research studies are not able to provide informed consent, either due to significant cognitive decline, or their designation of someone else as their legal proxy. When this occurs, we do not offer them study participation because legally, they are unable to consent, even if currently, their cognitive capacities seem intact. We have generally assessed this through a series of branching questions to determine their legal and cognitive capacity for consent. |
| Country | Name | City | State |
|---|---|---|---|
| United States | UVA Infectious Diseases Clinic | Charlottesville | Virginia |
| Lead Sponsor | Collaborator |
|---|---|
| University of Virginia |
United States,
Ingersoll K, Dillingham R, Reynolds G, Hettema J, Freeman J, Hosseinbor S, Winstead-Derlega C. Development of a personalized bidirectional text messaging tool for HIV adherence assessment and intervention among substance abusers. J Subst Abuse Treat. 2014 — View Citation
Ingersoll KS, Dillingham RA, Hettema JE, Conaway M, Freeman J, Reynolds G, Hosseinbor S. Pilot RCT of bidirectional text messaging for ART adherence among nonurban substance users with HIV. Health Psychol. 2015 Dec;34S:1305-15. doi: 10.1037/hea0000295. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Missed Visit Proportion (MVP) | The primary outcome measure for ADHERENCE is missed visit proportion (MVP) across a 6 month follow-up period, used to derive the sample size for this stage 1 RCT. The primary outcome measure for DRUG USE is a Timeline Follow-back to gather 90 day retrospective reports of daily drug use. | 6 months | |
| Secondary | pharmacy refill data | Secondary outcome measures for adherence will be unannounced telephone pill counts and pharmacy refill data; these will be assessed and used to plan a larger, more definitive study, if the intervention shows promise. Pharmacy compliance can be measured directly in the large subset of patients who fill their prescription through the Virginia ADAP Program. Unannounced pill counts conducted by phone can be assessed for all participants and used to measure medication adherence. | 6 months | |
| Secondary | Secondary: text messaged adherence and drug use data | We will have daily data from participants' text messages about their adherence behavior. Comparing texts sent by participants about adherence to TLFB will allow us to test the level of agreement about adherence by two distinct measures, one (TLFB) with known properties. Differences in the magnitude and direction of the effect of the intervention for different outcomes will help us choose an outcome for the larger trial, and may shed light on the particular aspects of behavior that the text messaging tool can influence. | during 12 week intervention period |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |